Wockhardt Ltd

Wockhardt Ltd

$WOCKPHARMAPharmaceuticalsNSEBSE

Wockhardt Ltd (WOCKPHARMA) last traded at ₹1,894, a market capitalisation of ₹30,777 crore, on a P/E of 77.2. Over the past 52 weeks the stock has ranged between ₹1,087 and ₹2,422. Wockhardt Ltd last reported results for the quarter ended Jun 2026, with sales of ₹929 crore and net profit of ₹107 crore. Figures are as of 25 Aug 2026 and are not real time.

Wockhardt Ltd share price and key metrics

Current price
₹1,894
Market cap
₹30,777 cr
Stock P/E
77.2
Book value
₹304
ROE
6.11%
ROCE
7.55%
Dividend yield
0.00%
52w high / low
2422/1087

Metrics as of 25 Aug 2026. Not real time.

Wockhardt Ltd quarterly results

In the quarter ended Jun 2026, sales were ₹929 cr, up 25.9% from ₹738 cr a year earlier. Net profit turned positive at ₹107 cr.

Wockhardt Ltd consolidated quarterly results, figures in ₹ crore
₹ croreSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales809721743738782888965929
Expenses699593679666604711740737
Operating profit1101286472178177225192
OPM %14%18%9%10%23%20%23%21%
Other income9815-7721156731
Interest7360484855605052
Depreciation5555535653655355
Profit before tax-921-22-1099167189116
Tax %78%5%105%-1%10%9%13%8%
Net profit-1620-45-1088261164107
EPS (₹)-1.430.86-1.54-5.544.803.6310.226.52

Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.

Wockhardt Ltd annual results

Wockhardt Ltd annual profit and loss, figures in ₹ crore
₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales2,7083,2302,6512,7983,0123,3733,564
Operating profit-6329810291393652772
OPM %-2.3%9%3.9%3.2%13%19%22%
Net profit688-279-621-472-57199414
EPS (₹)47.64-16.94-38.80-30.18-2.8913.1125.17

TTM is the trailing twelve months to the most recent quarter.

Wockhardt Ltd growth and returns

Compounded Sales Growth
10 Years
-3%
5 Years
4%
3 Years
8%
TTM
18%
Compounded Profit Growth
10 Years
1%
5 Years
-19%
3 Years
43%
TTM
983%
Stock Price CAGR
10 Years
10%
5 Years
38%
3 Years
103%
1 Year
31%
Return on Equity
10 Years
-2%
5 Years
-3%
3 Years
-1%
Last Year
6%

Wockhardt Ltd shareholding pattern

Promoters held 49.09% at Jun 2026, broadly unchanged since Jun 2025. FIIs 7.23% and DIIs 9.24%.

Wockhardt Ltd shareholding pattern by quarter, in percent
% heldSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters51.99%49.09%49.09%49.09%49.09%49.09%49.09%49.09%
FIIs6.70%6.54%6.82%7.29%7.10%7.00%7.09%7.23%
DIIs5.08%9.82%10.58%11.00%11.00%10.55%10.96%9.24%
Government0.02%0.02%0.02%0.02%0.02%0.02%0.04%0.02%
Public36.21%34.54%33.50%32.60%32.79%33.36%32.84%34.44%
No. of shareholders1,38,1421,42,7101,41,7991,46,9181,37,9461,42,2741,39,0161,66,518

As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.

Wockhardt Ltd corporate filings

  • Pursuant to Regulation 30 read with Para A of Part A of Schedule III of SEBI (LODR) Regulations, 2015, the Proceedings of the 27th AGM of the CompanyAGM/EGMhigh impact
    Filing PDF

    Cruxal's analysis: Wockhardt Limited has successfully concluded its 27th Annual General Meeting, securing…

    Read the full analysis
  • Pursuant to Regulation 32(6) of SEBI (LODR) Regulations 2015, read with Regulation 173A of SEBI (ICDR) Regulations, 2018, please find enclosed Monitoring Agency Report towards utilisation ....Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Wockhardt Ltd has filed the Monitoring Agency Report issued by CRISIL Ratings Limited…

    Read the full analysis
  • Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseCompany Updatelow impact
    Filing PDF

    Cruxal's analysis: Wockhardt Ltd has announced the launch of the 'Wockhardt Antibiotic Academy,' a platform…

    Read the full analysis
  • Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release on the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2026Company Updatehigh impact
    Filing PDF

    Cruxal's analysis: Wockhardt Limited has delivered a robust performance for Q1 FY27, reporting a total…

    Read the full analysis
  • Pursuant to Regulation 30 of SEBI Listing Regulations, Board of Directors at its meeting held today i.e 10th August, 2026 has approved the Unaudited Financial Results (Standalone and Consolidated) ....Board Meetinghigh impact
    Filing PDF

    Cruxal's analysis: Wockhardt Limited has announced its unaudited financial results for the quarter ended 30…

    Read the full analysis
  • Pursuant to Regulation 30 read with schedule III (Part A Para A) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find ....Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Wockhardt Ltd has released newspaper extracts regarding an addendum to the notice of its…

    Read the full analysis
  • Addendum To The Notice Of 27Th Annual General Meeting Of The CompanyAGM/EGMlow impact
    Filing PDF

    Cruxal's analysis: Wockhardt Limited has issued an addendum to its 27th Annual General Meeting notice…

    Read the full analysis
  • Wockhardt Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve Pursuant to Regulation 29(1) of SEBI ....Board Meetinglow impact
    Filing PDF

    Cruxal's analysis: Wockhardt Limited has announced that its Board of Directors will convene a meeting on…

    Read the full analysis

This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.

Track Wockhardt Ltd

Cruxal reads every Wockhardt Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.

Cruxal publishes market data and coverage for information only. Nothing here is investment advice.

Wockhardt Ltd (WOCKPHARMA) Results, Financials & Share Price | Cruxal